117 related articles for article (PubMed ID: 38305826)
1. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P
Am J Ther; 2024 Feb; ():. PubMed ID: 38305826
[No Abstract] [Full Text] [Related]
2. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
3. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
[TBL] [Abstract][Full Text] [Related]
4. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
5. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
6. Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Khalid S; Yasar S; Khalid A; Spiro TP; Haddad A; Daw H
Cureus; 2018 May; 10(5):e2701. PubMed ID: 30062075
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
8. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
Andersson ML; Johansson H; Österborg A; Månsson-Broberg A; Hansson L; Palma M
Eur J Haematol; 2023 Nov; 111(5):748-756. PubMed ID: 37565648
[TBL] [Abstract][Full Text] [Related]
12. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett J; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong E; Leng S; Yang X; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2286-2295. PubMed ID: 37870435
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Santoro RC; Falbo M; Levato L; Iannaccaro P; Prejanò S
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):159-161. PubMed ID: 33273263
[TBL] [Abstract][Full Text] [Related]
17. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Gribben JG; Bosch F; Cymbalista F; Geisler CH; Ghia P; Hillmen P; Moreno C; Stilgenbauer S
Br J Haematol; 2018 Mar; 180(5):666-679. PubMed ID: 29318593
[TBL] [Abstract][Full Text] [Related]
18. Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.
Rasmussen KM; Patil V; Burningham Z; Yong C; Sauer BC; Halwani AS
Fed Pract; 2020 May; 37(Suppl 2):S44-S49. PubMed ID: 32952387
[TBL] [Abstract][Full Text] [Related]
19. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320
[TBL] [Abstract][Full Text] [Related]
20. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
